annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 47A Primary resistances to EGFR inhibitors (EGFRi) in HPV-positive and
-negative oropharyngeal squamous cell carcinoma (OSCC). (Abstract
#10591)
F. Perrone, B. Cortelazzi, M. Orsenigo, G. Jocollè, E. Tarantino, S. Brich, P. Bossi,
L. Locati, L. F. Licitra, S. Pilotti
Brd. 47B Implication of the alternative NF-kappa B pathway in prostate cancer
progression. (Abstract #10592)
I. Labouba, S. Mehairi, M. Latour, A. Mes-Masson, F. Saad
Brd. 47C Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and
temozolomide (TMZ) in neuroblastoma (NB). (Abstract #10593)
E. G. Lipsitz, V. Nguyen, H. Zhao, J. Ecsedy, J. M. Maris, P. C. Adamson,
Y. P. Mosse
Brd. 47D Use of protein pathway activation mapping of NSCLC to identify distinct
molecular subtypes and a prognostic signature for aggressive node-negative
tumors. (Abstract #10594)
A. Zupa, G. Improta, J. Deng, M. Aieta, P. Musto, L. A. Liotta, C. Belluco,
E. Mammano, J. D. Wulfkuhle, E. Petricoin III
Brd. 47E Nuclear expression of aryl hydrocarbon receptor and prognosis for nonsmall
lung cancer. (Abstract #10595)
H. Chang
Brd. 47F Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1
inhibitor with radiotherapy. (Abstract #10596)
K. Mason, J. Pickett, C. Ware, H. Hirai, P. Strack, S. D. Shumway, K. Ang,
T. A. Buchholz, L. Milas, C. A. Buser
Brd. 47G Antagonists of growth hormone-releasing hormone potentiate radiation
response in prostate cancer. (Abstract #10597)
M. Abdel-Wahab, A. Schally, F. Rick, L. Szalontay, J. Varga, Y. Shi, M. Zarandi,
A. Pollack
Brd. 47H Clinico-pathologic features of lung cancer with EML4-ALK translocation.
(Abstract #10598)
T. Mitsudomi, K. Suda, K. Tomizawa, Y. Yatabe
Brd. 48A Evaluation of ADAM28 as a serological and histochemical marker for nonsmall
cell lung cancers. (Abstract #10599)
H. Kuroda, M. Shimoda, M. Kawamura, H. Nomori, Y. Okada
Brd. 48B Effect of plasma SPARC on outcome in cancer models. (Abstract #10600)
N. Desai, M. Piacente, X. Liu, O. D’Cruz, L. Hwang, X. Lin, S. Ran, S. Markovic,
K. Motamed, V. N. Trieu
Brd. 48C Evaluation of the hedgehog pathway as a therapeutic target for preventing
the progress to invasive-stage from noninvasive-stage breast cancer.
(Abstract #10601)
M. Sozaki, M. Kubo, M. Kai, C. Kameda, H. Tanaka, H. Onishi, M. Nakamura,
M. Tanaka, M. Katano
Brd. 48D Effect of zoledronic acid acts on the interaction between mesenchymal stem
cells and breast cancer cells within the bone microenvironment. (Abstract
#10602)
N. Normanno, M. Gallo, L. Lamura, A. De Luca
Brd. 48E Clinical relevance of the detection of tumor cells in the bone marrow of
patients before lung cancer surgery. (Abstract #10603)
R. Nakahara, M. Anraku, A. Ui, N. Oohata, H. Matsuguma, S. Igarashi, K. Yokoi
Brd. 48F Molecular markers for epithelial-mesenchymal transition (EMT) and tumor
aggressiveness in breast carcinoma. (Abstract #10604)
S. Sethi, F. H. Sarkar, Q. Ahmed, S. Bandyopadhyay, Z. A. Nahleh, W. Sakr,
A. Munkarah, R. Ali-Fehmi
111
SATURDAY